Summative interaction between astaxanthin, Ginkgo biloba extract (EGb761) and vitamin C in Suppression of respiratory inflammation: A comparison with ibuprofen

Phytotherapy Research

Volumn 25, Issue 1, 2011, Pages 128-136

  Haines, David D ^a,b   Varga, Balazs ^a   Bak, Istvan ^a   Juhasz, Bela ^a   Mahmoud, Fadia F ^c   Kalantari, Heybatullah ^d   Gesztelyi, Rudolf ^a   Lekli, Istvan ^a   Czompa, Attila ^a   Tosaki, Arpad ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b UNIVERSITY OF CONNECTICUT   (United States)

^c KUWAIT UNIVERSITY   (Kuwait)

^d AHVAZ JUNDISHAPUR UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

astaxanthin; cAMP; cGMP; ginkgolide; ibuprofen; inflammation

Indexed keywords

ASCORBIC ACID; ASTAXANTHIN; GINKGO BILOBA EXTRACT; IBUPROFEN; OVALBUMIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTHMA; CELL INFILTRATION; CONTROLLED STUDY; EOSINOPHIL; GUINEA PIG; LUNG; MACROPHAGE; MALE; NEUTROPHIL; NONHUMAN; RESPIRATORY TRACT INFLAMMATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ASCORBIC ACID; ASTHMA; DRUG THERAPY, COMBINATION; GUINEA PIGS; IBUPROFEN; MALE; PLANT EXTRACTS; XANTHOPHYLLS;

ANIMALIA; CAVIA; GINKGO BILOBA;

EID: 78650631519     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.3160     Document Type: Article

References (42)

1. Asako H, Kubes P, Baethge BA, Wolf RE, Granger DN., 1992. Reduction of leukocyte adherence and emigration by cyclosporine and L683,590 (FK506) in postcapillary venules. Transplantation 54: 686-690.
2. Bagnis C, Deray G, Dubois M, et al,. 1996. Prevention of cyclosporin nephrotoxicity with a platelet-activating factor (PAF) antagonist. Nephrol Dial Transplant 11: 507-513.
3. Bjarnason I., 2007. Ibuprofen and gastrointestinal safety: a dose-duration-dependent phenomenon. J R Soc Med 100 (Suppl 48): 11-14.
4. Brochet D, Chermat R, DeFeudis FV, Drieu K., 1999. Effects of single intraperitoneal injections of an extract of Ginkgo biloba (EGb 761) and its terpene trilactone constituents on barbital-induced narcosis in the mouse. Gen Pharmacol 33: 249-256. (Pubitemid 29376463)
5. Busse WW., 1998. Leukotrienes and inflammation. Am J Respir Crit Care Med 157: S210-S213; discussion S247-S248.
6. Calabresse C, Nguer MC, Pellegrini O, Benveniste J, Richard Y, Thomas Y., 1992. Induction of high-affinity paf receptor expression during T cell activation. Eur J Immunol 22: 1349-1355.
7. Chan CC, Reid CM, Aw TJ, Liew D, Haas SJ, Krum H., 2009. Do COX-2 inhibitors raise blood pressure more than nonselective NSAIDs and placebo? An updated meta-analysis. J Hypertens 27: 2332-2341.
8. Chandrasekharan NV, Dai H, Roos KL, et al,. 2002. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci USA 99: 13926-13931.
9. Dajani EZ, Islam K., 2008. Cardiovascular and gastrointestinal toxicity of selective cyclo-oxygenase-2 inhibitors in man. J Physiol Pharmacol 59 (Suppl 2): 117-133.
10. El H, II, Malik SM, Alwakeel HR, Shaikh OS, Sasatomi E, Kandil HM., 2009. Celecoxib-induced cholestatic liver failure requiring orthotopic liver transplantation. World J Gastroenterol 15: 3937-3939.
11. Evans EG., 2003. Drug synergies and the potential for combination therapy in onychomycosis. Br J Dermatol 149 (Suppl 65): 11-13.
12. Fan L, Vonshak A, Zarka A, Boussiba S., 1998. Does astaxanthin protect Haematococcus against light damage? Z Naturforsch C 53: 93-100.
13. Feldman HA, McMahon TA., 1983. The 3/4 mass exponent for energy metabolism is not a statistical artifact. Respir Physiol 52: 149-163.
14. Grosser T., 2009. Variability in the response to cyclooxygenase inhibitors: toward the individualization of nonsteroidal anti-inflammatory drug therapy. J Investig Med 57: 709-716.
15. Hai CM., 2007. Airway smooth muscle cell as therapeutic target of inflammation. Curr Med Chem 14: 67-76.
16. Haines DD, Bak I, Ferdinandy P, et al,. 2000. Cardioprotective effects of the calcineurin inhibitor FK506 and the PAF receptor antagonist and free radical scavenger, EGb 761, in isolated ischemic/reperfused rat hearts. J Cardiovasc Pharmacol 35: 37-44.
17. Hamad AM, Clayton A, Islam B, Knox AJ., 2003. Guanylyl cyclases, nitric oxide, natriuretic peptides, and airway smooth muscle function. Am J Physiol Lung Cell Mol Physiol 285: L973-L983.
18. Harrington LS, Lucas R, McMaster SK, et al,. 2008. COX-1, and not COX-2 activity, regulates airway function: relevance to aspirin-sensitive asthma. FASEB J 22: 4005-4010.
19. Hawkey CJ., 2001. COX-1 and COX-2 inhibitors. Best Pract Res Clin Gastroenterol 15: 801-820.
20. Kakuta H, Zheng X, Oda H, et al,. 2008. Cyclooxygenase-1-selective inhibitors are attractive candidates for analgesics that do not cause gastric damage: design and in vitro/in vivo evaluation of a benzamide-type cyclooxygenase-1 selective inhibitor. J Med Chem 51: 2400-2411.
21. 4-treated rats. Methods Find Exp Clin Pharmacol 23: 79-84.
22. Kirkham P, Rahman I., 2006. Oxidative stress in asthma and COPD: antioxidants as a therapeutic strategy. Pharmacol Ther 111: 476-494.
23. Kose F, Besen A, Paydas S, et al,. 2009. Effects of selective Cox-2 inhibitor, rofecoxib, alone or combination with furosemide on renal functions and renal Cox-2 expression in rats. Clin Exp Nephrol 14: 22-27.
24. Kurashige M, Okimasu E, Inoue M, Utsumi K., 1990. Inhibition of oxidative injury of biological membranes by astaxanthin. Physiol Chem Phys Med NMR 22: 27-38.
25. Mahmoud FF, Abul HT, Haines DD, Abal AT, Wise JA., 2002. In vitro effects of ginkgolide B combined with cyclosporin A on T-lymphocyte activation and IL-5 expression in peripheral blood mononuclear cells from asthmatic subjects. Transplant Proc 34: 2958-2961.
26. Mahmoud FF, Haines DD, Abul HT, Abal AT, Onadeko BO, Wise JA., 2004. In vitro effects of astaxanthin combined with ginkgolide B on T lymphocyte activation in peripheral blood mononuclear cells from asthmatic subjects. J Pharmacol Sci 94: 129-136.
27. Mazur LJ., 2002. Ibuprofen was more protective against asthma morbidity than acetaminophen in asthmatic children with fever. ACP J Club 137: 108.
28. Moore N., 2007. Ibuprofen: a journey from prescription to over-the-counter use. J R Soc Med 100 (Suppl 48): 2-6.
29. Rao P, Knaus EE., 2008. Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition and beyond. J Pharm Pharm Sci 11: 81s-110s.
30. Ray A., 2009. Beyond debacle and debate: developing solutions in drug safety. Nat Rev Drug Discov 8: 775-779.
31. Santing RE, Meurs H, van der Mark TW, et al,. 1992. A novel method to assess airway function parameters in chronically instrumented, unrestrained guinea-pigs. Pulm Pharmacol 5: 265-272.
32. Saponara R, Bosisio E., 1998. Inhibition of cAMP-phosphodiesterase by biflavones of Ginkgo biloba in rat adipose tissue. J Nat Prod 61: 1386-1387.
33. Sasakawa Y, Sakuma S, Higashi Y, Sasakawa T, Amaya T, Goto T., 2000. FK506 suppresses neutrophil chemoattractant production by peripheral blood mononuclear cells. Eur J Pharmacol 403: 281-288.
34. Soberman RJ, Christmas P., 2003. The organization and consequences of eicosanoid signaling. J Clin Invest 111: 1107-1113.
35. Umetsu DT, McIntire JJ, Akbari O, Macaubas C, DeKruyff RH., 2002. Asthma: an epidemic of dysregulated immunity. Nat Immunol 3: 715-720.
36. Underwood DC, Osborn RR, Novak LB, et al,. 1993. Inhibition of antigen-induced bronchoconstriction and eosinophil infiltration in the guinea pig by the cyclic AMP-specific phosphodiesterase inhibitor, rolipram. J Pharmacol Exp Ther 266: 306-313.
37. Wallace JL., 1999. Distribution and expression of cyclooxygenase (COX) isoenzymes, their physiological roles, and the categorization of nonsteroidal anti-inflammatory drugs (NSAIDs). Am J Med 107: 11S-16S; discussion 16S-17S.
38. Wang X, Willen R, Wadstrom T., 2000. Astaxanthin-rich algal meal and vitamin C inhibit Helicobacter pylori infection in BALB/cA mice. Antimicrob Agents Chemother 44: 2452-2457.
39. Warner TD, Mitchell JA., 2002. Cyclooxygenase-3 (COX-3): filling in the gaps toward a COX continuum? Proc Natl Acad Sci USA 99: 13371-13373.
40. Wenzel SE., 1996. Abnormalities of cell and mediator levels in bronchoalveolar lavage fluid of patients with mild asthma. J Allergy Clin Immunol 98: S17-S21; discussion S33-S40.
41. Wenzel-Seifert K, Seifert R., 1993. Partial inhibition of human neutrophil activation by FK-506 at supratherapeutic concentrations. Naunyn Schmiedebergs Arch Pharmacol 348: 7-13.
42. WHO. 2005. WHO Model List of Essential Medicines. World Health Organization. 2005 [cited. Available from <